Current promising treatment strategy for glioblastoma multiform: A review

Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Sanjib Bahadur (Author), Arvind Kumar Sahu (Author), Pragya Baghel (Author), Suman Saha (Author)
Format: Book
Published: Frontiers Media S.A., 2019-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_db44536c8ec54f0a9a68ee63d2dadd3c
042 |a dc 
100 1 0 |a Sanjib Bahadur  |e author 
700 1 0 |a Arvind Kumar Sahu  |e author 
700 1 0 |a Pragya Baghel  |e author 
700 1 0 |a Suman Saha  |e author 
245 0 0 |a Current promising treatment strategy for glioblastoma multiform: A review 
260 |b Frontiers Media S.A.,   |c 2019-07-01T00:00:00Z. 
500 |a 10.4081/oncol.2019.417 
500 |a 1970-5557 
500 |a 1970-5565 
520 |a Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients. 
546 |a EN 
690 |a Glioblastoma 
690 |a temozolomide 
690 |a resistance 
690 |a targeted therapy 
690 |a Other systems of medicine 
690 |a RZ201-999 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Oncology Reviews, Vol 13, Iss 2 (2019) 
787 0 |n https://www.oncologyreviews.org/index.php/or/article/view/417 
787 0 |n https://doaj.org/toc/1970-5557 
787 0 |n https://doaj.org/toc/1970-5565 
856 4 1 |u https://doaj.org/article/db44536c8ec54f0a9a68ee63d2dadd3c  |z Connect to this object online.